Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup

<table>At 58 months of followup, the patient presented an BCVA of 20/30 and cirrus HD-OCT displayed typical changes of an occult CNV with a smaller quantity of subretinal fluid (white line), but persistence in the changes to the RPE.</table>

Case Reports in Medicine

fig8

Figure 8

Figure 8: Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup 

Figure 8 | Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup 